Answers are grounded in this paper and cite their sources.
Taxifolin is a naturally occurring bioactive flavonoid with potential preventive and therapeutic benefits for several diseases. However, the availability of taxifolin is currently limited due to production issues, such as low plant extraction yields and stereoselectivity in chemical synthesis. This study aimed to establish a method for stereoselective taxifolin production using microbial enzymes that can convert quercetin, an abundant substrate, into taxifolin. We evaluated the taxifolin-producing activity of a flavone reductase from Flavonifractor plautii JCM 32125T (FpFLR). Recombinant FpFLR was heterologously expressed in Escherichia coli and purified using affinity chromatography. The enzymatic properties of the purified enzyme were investigated. Quercetin was successfully transformed by purified FpFLR into (2R,3R)-taxifolin, accounting for 98% of the total taxifolin isomers. These results demonstrate the high stereoselectivity of FpFLR and suggest its potential as a biocatalyst for the stereoselective production of naturally occurring (2R,3R)-taxifolin from quercetin.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: